YLYao Liu

Yao Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yao Liu has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • En Luo

    State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China

    7 shared publications
  • Ding Ai

    State Key Laboratory of Experimental Hematology, Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin, China

    3 shared publications
  • Hanghang Liu

    State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China

    3 shared publications
  • Shibo Liu

    State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China

    3 shared publications
  • Yi Zhu

    NHC Key Laboratory of Hormones and Development; the Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics; Department of Physiology and Pathophysiology, Tianjin Medical University, Tianjin 300070, China

    3 shared publications
  • En Luo

    2 shared publications

Latest Publications

  • Open Access

    A Synthetic/Fibrotic Vascular Remodeling Program Associated with Arteriovenous Fistula Maturation Failure

    by Weiqi Qian, Pengcheng Wang, Jiawei Song, Liu Yao

    Background/Objectives: Arteriovenous fistula (AVF) maturation failure is associated with maladaptive vascular remodeling, but the cellular states and microenvironmental programs involved remain unclear. Methods: We integrated human single-cell, spatial, and bulk transcriptomic datasets to characterize remodeling-associated cell states and gene signatures. Regulatory network inference, computational perturbation, an external cAMP responsive element binding protein 3 like 1 (CREB3L1) -deficient mouse dataset, structural modeling, molecular docking, and TGF-β1 stimulation of human venous smooth muscle cells (SMCs) were used to investigate candidate mechanisms. Results: Single-cell analyses identified a putative SMC-associated state with ECM-related transcriptional features. Spatial analyses localized related remodeling programs in control veins and mature AVFs, while bulk analyses associated a niche-derived signature with maturation failure. Integrative regulatory network and cell–cell communication analyses further linked myofibroblast-derived TGF-β signaling to increased CREB3L1 target activity in SMCs; consistently, exogenous TGF-β1 stimulation promoted the nuclear accumulation of CREB3L1. In silico perturbation of CREB3L1 predicted suppression of the synthetic/fibrotic SMC program. Complementary transcriptional reversal screening, structural modeling, and molecular docking analyses nominated candidate compounds with potential to modulate this regulatory axis. Conclusions: Our study generates a multiscale transcriptomic map of AVF maturation failure, identifying spatial ECM-remodeling signatures that offer mechanistic insights into AVF pathogenesis.

  • Engineering biomaterial-mediated delivery for osteoarthritis: targeting aging mechanisms to reestablish joint homeostasis

    by Xuehan Tang, Shibo Liu, Hanghang Liu, Yao Liu, Ze He, Qiheng Yang, En Luo

    Biomaterials have emerged as versatile platforms for targeting aging-related pathways in osteoarthritis (OA), owing to their capacity for localized delivery, controlled release, microenvironmental regulation, and tissue repair.

  • Macrophage USP9X attenuates colitis by restricting oncostatin M production via K27-linked deubiquitination of STAT1

    by Tao Zhang, Fanyi Meng, Wenjing Zhao, Xiangyu Meng, Jie Xiong, Feifei Chu, Yadi Lan, Jingyi Wang, Qi Chen, Weilong Zhong, et al.

    Dysregulated posttranslational modifications drive inflammatory bowel disease (IBD) pathogenesis, yet the specific roles of deubiquitinases in intestinal macrophages remain poorly characterized. Here, we identify ubiquitin-specific peptidase 9X (USP9X) as a critical negative regulator of intestinal inflammation. USP9X expression is reduced in UC patients and inversely correlated with disease severity. Myeloid-specific deletion of USP9X exacerbates colitis in both DSS- and TNBS-induced models, whereas its overexpression ameliorates disease. Mechanistically, USP9X interacts with signal transducer and activator of transcription 1 (STAT1) and removes K27-linked polyubiquitin chains from lysine 544. The loss of USP9X enhances STAT1 nuclear translocation and transcriptional activity, resulting in the upregulation of oncostatin M (OSM) expression and exacerbating inflammation. Mutation of STAT1 at K544 attenuated both basal and USP9X knockdown-induced responses. Notably, neutralizing OSM abrogates the exacerbated colitis phenotype in USP9X-deficient mice. These findings define a USP9X-STAT1-OSM axis that connects ubiquitin editing to transcriptional regulation and represents a potential therapeutic target for IBD. USP9X suppresses STAT1 transcriptional activation by editing K27-linked ubiquitination at lysine 544 In wild-type conditions, USP9X removes K27-linked polyubiquitin chains from STAT1 at lysine 544, limiting its nuclear retention and transcriptional activity. In macrophages, loss of USP9X leads to enhanced K27-linked ubiquitination of STAT1, enhanced STAT1 nuclear translocation, and increased STAT1 occupancy at the Osm promoter, resulting in elevated OSM expression. AAV9-mediated USP9X delivery ameliorates intestinal inflammation by restoring USP9X expression. USP9X, ubiquitin-specific peptidase 9X; STAT1, signal transducer and activator of transcription 1; OSM, Oncostatin M. (Created with Biorender).


  • Inflammatory cytokine scavenging and macrophage metabolism reprogramming to orchestrate inflammatory bone regeneration

    by Ze He, Yu-Qing Mu, Wen-Dong Gao, Yao Liu, Shi-Bo Liu, Hang-Hang Liu, Jia-Wei Xing, Wen-Jia Han, Guo-Hou Miao, En Luo, et al.

    Inflammatory bone defects pose significant challenges due to persistent inflammation and impaired bone regeneration in infectious disorders such as periodontitis and osteomyelitis. Current therapeutic strategies often fail to address immune dysregulation and defective osteogenesis simultaneously. Here, we developed an inflammatory cytokine-scavenging approach using anti-inflammatory M2 macrophage membranes to neutralize inflammatory cytokines in the bone healing environment, and synthesized selenium-doped bioactive glass nanoparticles (Se-NPs) to reprogram macrophage metabolism, thereby creating a favorable environment for inflammatory bone regeneration. The nanospheres were prepared by encapsulating Se-NPs within M2 macrophage membranes (M2@Se-NPs). These nanospheres harness their anti-inflammatory capacity via cytokine receptors to scavenge TNF-α and IL-6, while the sustained release of selenium ions reprograms macrophage metabolism via the NRF2/NF-κB pathway, restoring mitochondrial homeostasis and promoting M2 polarisation. In vitro, M2@Se-NPs effectively attenuated macrophage inflammation and inhibited NF-κB activation. Conditioned medium from M2@Se-NP-treated macrophages further enhanced the osteogenic differentiation of bone marrow stromal cells and promoted angiogenesis of human umbilical vein endothelial cells. In a murine inflammatory cranial defect model, M2@Se-NPs not only mitigated local inflammation by downregulating TNF-α and upregulating ARG-1, but also significantly enhanced osteogenic differentiation and bone matrix formation. This study demonstrates the triple therapeutic roles of M2@Se-NPs in immune modulation, angiogenesis, and bone repair, presenting a novel biomimetic solution for inflammatory bone regeneration.


  • Open Access

    Sequential immunomodulation-osteogenesis by zinc-loaded nanotopographical fibrous membranes for inflammatory alveolar bone regeneration

    by Bo-Wen Zheng, Jia-Cheng Lv, Cui-Ting Gao, Jia-Wei Xing, Zi-Li Zheng, Bao Deng, Wen-Jia Han, Xue-Han Tang, Ze He, Shi-Bo Liu, et al.


  • Homocysteine activates endothelial TP receptor to promote von Willebrand factor secretion and thrombosis

    by Jiachen Zhang, Xinyu Jia, Ping Zhu, Mengzheng Zhao, Haodong Du, Xinyi Yu, Jing Huang, Yegong Xie, Yequn Chen, Yi Zhu, et al.


  • Tailored surface topographical scaffolds: a breakthrough in osteoarthritic cartilage and subchondral bone defect repair

    by Bowen Zheng, Jiawei Xing, Xuehan Tang, Ze He, Qingran Tang, Shibo Liu, Yin Xiao, Jiazhuang Xu, En Luo, Yao Liu

    This review highlights tailored surface topographies in scaffolds for osteoarthritis therapy, summarizing design principles, fabrication methods, and micro/nano topography effects on cell behavior via signaling pathways, guiding future therapies.


  • Inhibition of IP3 (Inositol 1,4,5-Trisphosphate) Receptors Retards SARS-CoV-2-Induced Endothelial von Willebrand Factor Secretion and Thrombosis

    by Xin-Yi Yu, Xin-Yu Jia, Ting-Yu Wang, Yan-Hong Zhang, Hao Song, Kan Li, Zhuo-Zheng Chen, Yi Zhu, Liu Yao

    Patients with coronavirus disease 2019 (COVID-19) are at high risk of developing a hypercoagulable state and thrombosis. The von Willebrand factor (vWF) produced by endothelial cells (ECs) is a critical thrombosis regulator. We previously found that cytoskeleton-associated protein 4 (CKAP4) is a novel receptor for the spike protein of severe acute respiratory syndrome coronavirus-2 and is involved in COVID-19-associated coagulopathy. However, the underlying mechanism involved remains unclear. This study aimed to explore the signaling pathways involved in spike protein-CKAP4-induced vWF secretion and thrombosis. Treatment of ECs with the spike protein significantly induced vWF secretion, coagulation factor VIII (FVIII)–vWF binding, and platelet adhesion to ECs, which were blocked by the selective intracellular calcium chelator, BAPTA-AM. Furthermore, using several calcium channel-blocking drugs and small-molecule inhibitors, we found that calcium released from the endoplasmic reticulum (ER) is involved in this process. IP3 (inositol 1,4,5-trisphosphate) receptors (IP3Rs) inhibition ameliorated spike protein-induced vWF secretion, FVIII–vWF binding affinity, and platelet adhesion to ECs. Specifically, the knockdown of IP3R1, a crucial type of IP3Rs, reversed spike protein-induced endothelial vWF secretion, and the procoagulant state. Moreover, KT-362, an investigational and clinically relevant antihypertensive drug targeting IP3Rs-mediated calcium release, repressed spike protein-induced endothelial vWF secretion. Conversely, the IP3Rs agonist promoted endothelial vWF secretion, which was not affected by CKAP4 knockdown. In vivo treatment of endothelial-specific human CKAP4 overexpression mice with KT-362 retarded spike protein-induced vWF secretion and thrombosis. Thus, IP3Rs mediated calcium release from the ER and contributed to spike protein-induced vWF secretion and thrombosis, making them potential therapeutic targets for COVID-19-associated coagulopathy.


  • Open Access

    Biodegradable Zn-2Cu-0.5Zr alloy promotes the bone repair of senile osteoporotic fractures via the immune-modulation of macrophages

    by Huanzhong Ji, Gang Shen, Hanghang Liu, Yao Liu, Junyu Qian, GuoJiang Wan, En Luo

    Delayed bone-healing of senile osteoporotic fractures remains a clinical challenge due to the alterations caused by aging in bone and immune systems. The novel biomaterials that address the deficiencies in both skeletal cells and immune systems are required to effectively treat the bone injuries of older patients. Zinc (Zn) has shown promise as a biodegradable material for use in orthopedic implants. To address the bone-healing deficiencies in elderly patients with bone injuries, we developed a biodegradable Zn-based alloy (Zn-2Cu-0.5Zr) with enhanced mechanical properties, including a yield strength of 198.7 MPa and ultimate tensile strength of 217.6 MPa, surpassing those of pure Zn and Zn-2Cu alloys. Cytotoxicity tests conducted on bone marrow mesenchymal stem cells (BMSCs) and MC3T3-E1 cells demonstrated that the extracts from Zn-2Cu-0.5Zr alloy exhibited no observable cytotoxic effects. Furthermore, the extracts of Zn-2Cu-0.5Zr alloy exhibited significant anti-inflammatory effects through regulation of inflammation-related cytokine production and modulation of macrophage polarization. The improved immune-osteo microenvironment subsequently contributed to osteogenic differentiation of BMSCs. The potential therapeutic application of Zn-2Cu-0.5Zr in senile osteoporotic fracture was tested using a rat model of age-related osteoporosis. The Zn-2Cu-0.5Zr alloy met the requirements for load-bearing applications and accelerated the healing process in a tibial fracture in aged rats. The imaging and histological analyses showed that it could accelerate the bone-repair process and promote the fracture healing in senile osteoporotic rats. These findings suggest that the novel Zn-2Cu-0.5Zr alloy holds potential for influencing the immunomodulatory function of macrophages and facilitating bone repair in elderly individuals with osteoporosis.